The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 2008, Pages 115-119

  Kobayashi, Mariko ^a   Takagi, Miho ^c   Fukumoto, Kyoko ^a   Kato, Ryuji ^b   Tanaka, Kazuhiko ^b   Ueno, Kazuyuki ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c NONE

Author keywords

Bucolome; CYP2C9; Interaction; Losartan; Pharmacokinetics

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; BUCOLOME; LOSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BARBITURIC ACID DERIVATIVE; CYP2C9 PROTEIN, HUMAN; ENZYME INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE COMPARISON; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; DRUG ANTAGONISM; DRUG INTERACTION; WISTAR RAT;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BARBITURATES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; LOSARTAN; MALE; RATS; RATS, WISTAR;

EID: 43749095175     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.115     Document Type: Article

References (16)

1. Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., et al.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev, 45: 205-251 (1993).
2. Lo, M.W., Goldberg, M. R., McCrea, J. B., Lu, H., Furtek, C. I. and Bjornsson, T. D.: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther, 58: 641-649 (1995).
3. Williamson, K. M., Patterson, J. H., McQueen, R. H., Adams, K. F. and Pieper, J. A.: Effect of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther, 63: 316-323 (1998).
4. Yasar, U., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman-Sundberg, M., Dahl, M. L., et al.: The role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos, 29: 105-106 (2001).
5. O'Reilly, R. A., Trager, W. F., Motley, C. H. and Howald, W.: Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. J Clin Invest, 65: 746-753 (1980).
6. O'Reilly, R. A.: Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation, 65: 202-207 (1982).
7. Matsumoto, K., Ishida, S., Ueno, K., et al.: The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin. J Clin Pharmacol, 41: 459-464 (2001).
8. Ritter, M. A., Furtek, C. I. and Lo, M.W.: An improved method for the simultaneous determination of losartan and its major metabolite, E3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal, 15: 1021-1029 (1997).
9. Gonzalez, L., Lopez, J. A., Alonso, R. M. and Jimenez, R. M.: Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogy A, 949: 49-60 (2002)
10. Oradell, N. J.: Merck & Co. Cozaar tablets. In: Physicians' Desk Reference. 50th ed. Medical Economics Company, 1996, pp. 1628-1630 (1996).
11. Munafo, A., Christen, Y., Nussberger, J., Shum, L. Y., Borland, R. M., Lee, R. J., Waeber, B., Biollaz, J. and Brunner, H. R.: Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther, 51: 513-521 (1992).
12. Ohtawa, M., Takayama, F., Saitoh, K., Yoshinaga, T. and Nakashima, M.: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol, 35: 290-297 (1993).
13. Stearns, R. A., Doss, G. A., Miller, R. R., Chiu, S.-H. L.: Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753. Drug Metabo Dispos, 19: 1160-1162 (1991).
14. Stearns, R. A., Miller, R. R., Doss, G. A., Chakravarty, P. K., Rosegay, A., Gatto, G. J. and Chiu, S.-H. L.: The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metabo Dispos, 20: 281-287 (1992).
15. Takayama, F., Saito, K., Yoshinaga, T., Morita, M., Hata, S., Esumi, Y., Jin, Y. and Okamura, Y.: Metabolic fate of losartan, a new angiotensin II receptor antagonist (1): absorption, distribution, metabolism and excretion after single administration in rats. Xenobio Metabol Dispos, 10: 223-243 (1995) (in Japanese).
16. Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, N. and Yokoi, T.: Inhibitory effects of amiodarone and its Ndeethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol, 49: 244-253 (2000).